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Abstract
Introduction: Susceptibility to head and neck squamous cell carcinoma may be
modified by functional polymorphisms in genes involved in the folate pathway,
such as cystathionine beta-synthase (CBS). The CBS 844ins68 polymorphism is
associated with DNA methylation changes and cancer development. 
Material and methods: A case-control retrospective study was conducted in 
322 patients with head and neck squamous cell carcinoma and in 531 control
subjects without cancer. The polymerase chain reaction-restriction fragment
length polymorphism technique was used to genotype the polymorphism. For
statistical analysis, χ2 test was conducted to examine whether the genotypic
frequency of CBS 844ins68 was in Hardy-Weinberg equilibrium and multiple
logistic regression was used for comparisons between groups, and for
interactions between the polymorphism and risk factors and clinical
histopathological parameters.
Results: No significant difference in CBS 844ins68 genotypic distribution was
observed between the groups. Age > 50 years, male gender and tobacco
consumption were predictors of the disease with increased risk of 7.89 (95% CI:
5.56-11.21), 2.49 (95% CI: 1.72-3.62), 6.44 (95% CI: 4.63-8.96) and 2.29 times (95%
CI: 1.71-3.06) respectively. There was no association between the distribution of
the CBS 844ins68 genotype and risk factors for this disease. According to clinical
histopathological parameters, CBS 884ins68 polymorphism presented high
frequency in oral cavity (p < 0.05) and patients with the polymorphism presented
less survival time (p < 0.05). 
Conclusions: We concluded that the CBS 844ins68 polymorphism is not associated
with HNSCC risk and there is increased risk of this disease in male gender
individuals smokers aged over 50 years. In adittion, the polymorphism is more
frequent in patients with oral cavity as primary site and in patients with less
survival time.
Key words: genetic polymorphism, head and neck neoplasms, folate, metabolism,
genes.
Introduction
Head and neck squamous cell carcinoma (HNSCC) is the fifth most
common cancer worldwide and the most common neoplasm in the upper
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aerodigestive tract. In Brazil, nearly 14,120 new cases
of oral cancer are expected in 2010, comprising
3,790 in women and 10,330 in men [1]. Despite
some advances in conventional therapies, including
surgery, radiation and chemotherapy, the overall
survival (OS) rate for HNSCC has not significantly
improved in the last three decades [2].
The HNSCC anatomical region includes tumours
of the oral cavity, pharynx and larynx and the
most common histological type is squamous cell
carcinoma, present in 95% of cases [2, 3]. Alcohol
and tobacco use are common factors for HNSCC.
Additionally, evidence is accumulating for a role of
folate in cancer. Studies have shown a relationship
between polymorphisms of genes involved in
folate metabolism and the HNSCC risk because of
their influence on methylation and synthesis of
DNA [2, 4-11].
Methylation is responsible for gene expression
control, chromatin structure stability and the
maintenance of genomic stability. Folate, the methyl
donor in reaction to cellular methylation, regulates
the synthesis, methylation and repair of DNA when
present in the body in adequate amounts. When
folate is altered in consequence of polymorphism
in this pathway, it disrupts the cell cycle and
consequently may lead to cancer [5, 12-14].
The  CBS  gene encodes cystathionine beta
synthase (CBS), involved in the folate pathway,
which is the central enzyme in the transsulfuration
pathway that irreversibly metabolizes homocysteine
(Hcy) (removes Hcy from the methionine) to
cystathionine. It is polymorphic in nucleotide 
844 – exon 8 (CBS 844ins68) with an insertion of
68 base pairs. Although the biological impact of this
polymorphism remains unclear, it seems to be
associated with reduction of Hcy levels and changes
in DNA methylation because of the low availability
of S-adenosylmethionine (SAdoMet), the main
methyl donor for methylation reactions, and
consequently DNA hypomethylation and carcino  -
genesis may occur [15-17]. 
The study of Le Marchand et al. [18] showed that
the CBS 844ins68 variant allele may be protective
against colorectal cancer, but this association occurs
together with other polymorphisms of the folate
pathway. The study of Pufulete et al. [19] did not
find an association with colorectal cancer. Other
studies also did not confirm an association between
the polymorphism and carcinomas of the upper
gastrointestinal tract [20] and prostate cancer [21]. 
The association between head and neck
squamous cell carcinoma and CBS  844ins68
polymorphism has not been tested until now; thus,
we have conducted this case-control study in 853 in  -
di  viduals to investigate the association between
CBS 844ins68 polymorphism and HNSCC aetiology.
Therefore, this study aimed to investigate the
frequency of CBS 844ins68 in head and neck
squamous cell carcinoma patients, to compare the
results with individuals without cancer, and to
evaluate the association of the polymorphism with
risk factors (tobacco and alcohol habits) and clinical
histopathological parameters.
Material and methods
Study subjects
At first, the study protocol was approved by the
National Ethics Committee (CONEP – 5566/2005;
SISNEP 0976.0.140.000-05).
The retrospective study population included
a total of eight hundred and fifty-three subjects
(322 patients and 531 controls) with a mean age of
52.5 ±13.7 years. The case group (86.7% men and
13.3% women) was treated at the Hospital de Base,
a Public Institution, Sa ~o José do Rio Preto, Sa ~o Paulo,
Brazil. Diagnosis was made from pathological
specimens after either total excision or biopsy.
Patients with squamous cell carcinoma tumour cell
types were included and patients previously treated
for tumours were excluded. 
The tumours were classified according to the
TNM classification following three criteria: extension
of the tumour (T), presence of regional lymph node
involvement (N) and presence of metastasis at
a distance (M) [22]. The clinical stage (TNM) was
used to analyse aggressiveness, with tumours being
grouped as non-aggressive (stage I and II) and
aggressive (stage III and IV). All required information
about clinical histopathological parameters was
obtained from the patients’ medical records. 
The control group comprised Brazilian blood
donors (72.3% men and 27.7% women) without
cancer according to the government guidelines for
blood donation which include tests for 20 related
diseases (http://www.hemonline.com.br/portarias/
rdc153/indexframe.htm). Individuals with family
history of cancer were excluded and individuals
aged over 40 years were included in this study. Each
eligible subject was interviewed to obtain data on
age, gender, smoking habits, use of alcohol and
familial history of cancer. 
The variables analysed were gender, exposure to
risk factors (tobacco and alcohol consumption), 
and primary site of occurrence, aggressiveness,
extension of the tumour and lymph node
involvement. Individuals who had smoked more than
100 cigarettes during their lifetime were considered
smokers. Individuals who drank four units of alcohol
per week were considered alcohol consumers [23, 24]. 
Genotyping of CBS 844ins68 
To determine the individual genotypes, genomic
DNA was obtained from peripheral blood according
to the technique of Miller et al. [25]. Molecular
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analysis of the CBS 844ins68 polymorphism was
performed according to PCR technique (polymerase
chain reaction) observing the difference in size of
amplification products, using primer sequences
described by Dutta et al. [26].
Amplification was obtained with initial
denaturation at 94°C for 4 min, followed by 
30 cycles of 1 minute of DNA denaturation at 94°C,
1 min of primer annealing at 62°C and 1 min of
extension at 72°C. A final extension of 5 min at 72°C
was carried out. The PCR products were run onto
1.5% agarose gel, stained with ethidium bromide
and visualized in UV illumination. The CBS gene
thus included (I) or lacked (N) a 68 base pairs (bp)
insertion at exon 8. The major allele (I) presented
a 239 bp fragment and the normal allele presented
a 171 bp fragment. Fragment sizes were estimated
by comparing with a 100 bp DNA size marker. 
Statistical analysis
Statistical analysis was performed using Minitab
software (Windows, Version 14.0) and the BioEstat
program. Chi-square tests were conducted to
examine whether the genotype frequency of CBS
844ins68 was in Hardy-Weinberg equilibrium (HWE). 
Differences in gender (reference: female),
tobacco (reference: non-smokers) and alcohol habits
(reference: non-drinkers) between the cases and
controls were evaluated using multiple logistic
regression analysis. This model was also used to
determine the interaction effect between the
genetic polymorphism and variables related to head
and neck squamous cell carcinoma. 
The clinical histopathological parameters were
analysed by multiple logistic regression. Tumours
were classified as low T (T1, T2) and high T (T3,
T4). The N classification was dichotomized into
no lymph node involvement (N0) and involvement
(N1, N2, N3). Tumours were divided into early
stage (stages I and II) and advanced stage (stages
III and IV) categories. A p value < 0.05 was
considered statistically significant. Results are
shown as odds ratio (OR) and 95% confidence
intervals (95% CI). 
The Kaplan-Meier method was used to evaluate
survival rates and recurrence time of disease. The
log-rank test was used to assess differences related
to the different genotypes.
Results
Demographic data and lifestyle factors
The case group with a mean age of 58.4 (9.9)
years presented a predominance of tobacco (80.7%)
and alcohol consumers (69.2%). The mean age of
the control group was 47.4 (13.1) years, 40.4%
tobacco users and 49.2% alcohol consumers. 
As matching demographic data and risk factors
between patients with cancer and control
individuals was not possible, multivariable analysis
was performed to adjust these variables. There
were statistically significant differences between
patients and controls according to age > 50 years
(OR 7.89, 95% CI: 5.56-11.21, p < 0.05), male gender
(OR 1.05, 95% CI: 1.05-2.67, p < 0.05) and tobacco
users (OR 4.09, 95% CI, 2.77-6.03, p < 0.05). 
CBS genotype
The Hardy-Weinberg equilibrium showed that
the genotypic distributions were not expected in
both groups and they were not in equilibrium (case:
χ2 = 4.98, p = 0.02 and control: χ2 = 8.05, p = 0.004).
The genotypic and allelic distributions of the CBS
844ins68 polymorphism were compared between
the groups and did not show statistically significant
differences. Of 854 individuals studied, 702 (82.2%,
443 controls and 259 patients) comprising did not
have the polymorphism; 18 (2.1%, 10 controls and
8 patients) presented CBS 844ins68 polymorphism,
and 134 (15.7%, 78 controls and 56 patients) had
the heterozygous genotype for the polymorphism
(Table I).
The potential interaction between the
distribution of the CBS 844ins68 genotype and
exposure to risk factors for head and neck
CBS 844ins68 polymorphism Patients, n (%) Controls, n (%)  OR (95% CI) p
Genotypes  n = 322 n = 531
NN (Non-insertion) 258 (80) 443 (83.4) 1.00 (ref)
IN (Heterozygous) 56 (17.5) 78 (14.6) 1.15 (0.74-1.79) 0.53
II (Polymorphic) 08 (2.5) 10 (2.0)
Alleles
Non-insertion (N) 68 bp 315 (83.1) 521 (82.8) 1.00 (ref)
Insertion 68 bp(I) 64 (16.9) 88 (17.2) 1.20 (0.85-1.71) 0.30
NN – 68 bp non-insertion, IN – heterozygous – CBS 844ins68, II – CBS 844ins68 polymorphic. Adjusted for age, gender, tobacco and alcohol
habits. The genotypes was calculated for polymorphic homozygous individuals or carrying risk allele heterozygous vs. wild-type homozygous. 
p < 0.05 was considered significant. There was no difference statistically significant (multiple logistic regression)
Table I. Distribution of the CBS 844ins68 polymorphism between HNSCC patients and controls
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squamous cell carcinoma are shown in Table II, with
no statistical difference.
Clinical histopathological parameters and CBS
polymorphism 
Only patients with complete pathological data
were considered for this analysis. There were
significant associations of individuals with IN and
II genotypes (at least one 68p insertion allele) with
oral cavity (OR 1.93, 95% CI: 1.10-3.40, p < 0.05)
(Table III). The analysis of metastasis classification
was not performed since all patients were classified
as M0. 
The Kaplan-Meier survival curves by genotype
are presented in Figure 1. There was an association
between polymorphism and survival time 
(p = 0.02) (Figure 1A), and no association between
polymorphism and recurrence time of the disease
(Figure 1B, p = 0.52). 
Variables NN genotype OR (95% CI) IN and II genotypes OR (95% CI)* p
(case/controls)( cases/controls)
Age 
< 50 53/313 1.00 (ref) 10/60 1.19 (0.55–2.57) 0.66
> 50 205/130 1.00 (ref) 54/28 1.18 (0.68–2.03) 0.55
Gender
Female 34/125 1.00 (ref) 08/22 1.34 (0.49–3.65) 0.56
Male 224/318 1.00 (ref) 56/66 1.12 (0.68–1.83) 0.65
Tobacco habits
No 47/261 1.00 (ref) 12/55 1.14 (0.52–2.50 0.73
Yes 211/182 1.00 (ref) 52/33 1.14 (0.66–1.95 0.64
Alcohol habits
No 81/221 1.00 (ref) 18/48 1.10 (0.55–2.19) 0.78
Yes 177/222 46/40 1.21 (0.67–2.17) 0.53
Tobacco and alcohol habits
No 38/151 1.00 (ref) 08/36 0.79 (0.31–1.98) 0.61
Yes 168/112 42/21 1.04 (0.56–1.93) 0.90
CBS cystathionine β-synthase: NN – 68 bp non-insertion, IN – heterozygous – CBS 844ins68, II – CBS 844ins68 polymorphic genotype 
*Ajusted for age, gender, tobacco and alcohol habits. CBS IN and II genotype compared with variables – reference: CBS NN; p < 0.05 was considered
significant. None of the differences between groups were statistically significant by multiple logistic regression 
Table II. Odds Ratio of head and neck cancer related to CBS genotypes by age, gender, tobacco and alcohol habits
Variables NN genotype OR (95% CI) IN/II genotype OR (95% CI)** p
Site of tumor
Oral cavity 97 1.00 (ref) 33 1.93 (1.10–3.40) < 0.05
Pharynx 65 1.00 (ref) 15 0.92 (0.48–1.76) 0.92
Larynx 85 1.00 (ref) 12 0.83 (0.50–1.36) 0.45
Unknown primary site 11 1.00 (ref) 05 1.50 (0.46–4.88) 0.50
Tumor extension
T1/T2 106 1.00 (ref) 28 1.00 (ref)
T3/T4 118 1.00 (ref) 29 0.48 (0.27–0.86) 0.63
N involvement
No 11 1.00 (ref) 01 1.00 (ref)
Yes 213 1.00 (ref) 56 1.47 (0.37–5.75) 0.58
CBS cystathionine β-synthase: NN – 68 bp non-insertion, IN – heterozygous – CBS 844ins68, II – CBS 844ins68 polymorphic genotype
*The analysis was made to patients with complete data. CBS IN and II genotype compared with clinical histopathological parameters – reference:
CBS NN; p < 0.05 was considered significant. There was difference statistically significant between oral cavity and CBS polymorphism (multiple
logistic regression)
Table III. Distribution of the clinical histopathological parameters and CBS polymorphism*
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Discussion
The results showed that HNSCC is more
common in male smokers aged over 50 years.
Previous studies have shown that male gender,
alcohol and tobacco consumption are the most
important predisposing factors for this disease 
[2, 27-29]. In our study, however, alcohol
consumption was not associated with HNSCC.
A multicentre study confirmed that tobacco is
a strong risk factor for HNSCC independent of
alcohol consumption [30]. Moreover, studies in
animal models showed that alcohol did not have
a direct carcinogenic effect and it is not genotoxic.
This agent suppresses the removal of nitrosamine
molecules of low molecular weight released by the
tobacco in the liver through inhibition of multiple
isoforms of the cytochrome P450 superfamily. Thus,
there is an increase of nitrosamines to the post-
hepatic tissues and an increase in the formation of
DNA adducts [31-33]. 
Male gender remains the most affected by this
tumour type as shown in our findings. However, 
the female gender has been presenting higher
proportions [27, 29], due to the habits of the
smoking and alcohol consumption have increased
among women [2]. 
According to Hardy-Weinberg equilibrium (HWE)
analysis, our study showed that the CBS gene is not
in HWE. The departure from the HWE may result
from the random selection of the studied
individuals, the disease model adopted, and
evolutionary factors which can influence changes
in the genotype frequencies [34, 35]. On the other
hand, this disequilibrium should be expected,
considering that it reflects biological and genetic
characteristics in complex disease models [36]. 
In our case-control study the CBS 68 bp insertion
allele (I) was not statistically significantly associated
with HNSCC risk (OR 1.20, 95% CI: 0.85-1.71, 
p = 0.30); nor with heterozygous genotype (I/N) or
polymorphic homozygous genotype (I/I), with OR
of 1.15 (95% CI: 0.74-1.79, p = 53). We did not find
evidence that the CBS 844ins68 polymorphism may
contribute to the individual risk for the development
of head and neck squamous cell carcinoma, in as
studies of Kimura et al. [21] and Ott et al. [20] in
prostate and upper gastrointestinal tract cancer,
respectively. 
Ott et al. [20] investigated the insertion of 68 bp
in the CBS gene with susceptibility to carcinomas
of the upper gastrointestinal tract. They studied 
263 patients with oesophageal cancer, 89 patients
with Barrett’s oesophagus-associated oesophageal
adenocarcinoma, 144 with cardiac carcinoma, 
221 with gastric cancer and 257 healthy subjects,
and they did not find an association with these
neoplasms. The study of Kimura et al. [21] in 132
patients with prostate cancer and 150 individuals
without cancer, and the study of Pufullete et al. [19]
that investigated 35 patients with adenoma, 
28 patients with colorectal cancer and 76 controls
did not found association with cancer risk. 
The study of Le Marchand et al. [18] found an
association of CBS 844ins68 and cancer risk. They
investigated 727 Japanese, Caucasian, or Native
Hawaiian colorectal cases and 727 controls without
neoplasia matched for sex, age, and ethnicity and
showed that CBS 844ins68 variant allele may be
weakly protective against colorectal cancer, but this
effect occurs only if this variant acts together with
the T allele (variant) of MTHFR C677T polymorphism. 
Our results for a potential interaction between
the distribution of the CBS 844ins68 genotype and
exposure to risk factors for head and neck
squamous cell carcinoma did not show any
100
90
80
70
60
50
40
0 40 80 120
Survival time [months]
Figure 1. Kaplan-Meier curves for the survival time 
(p = 0.02) (A) and recurrence time (p = 0.89) (B) for
patients  according to the CBS 844ins68 poly  -
morphism. There was statistical difference between
the curve for subjects with at least one polymorphic
allele (I or IN genotype) with survival time
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statistically significant association. Kimura et al. [21]
found that the insertion allele was slightly more
prevalent among females in homozygous or
heterozygous form in the control group, and the
polymorphic allele was rarer in older patients, but
these differences were not statistically significant.
This polymorphism resides in a key enzyme of
the one-carbon metabolism pathway and it may
result in aberrant DNA synthesis which may result
in uncontrolled growth, but no study presented
significant results for CBS 844ins68 polymorphism
and cancer risk [15-17]. To our knowledge, this is
the first study of CBS 844ins68 and HNSCC risk and
despite the few studies in cancer, some studies
have found an association of this polymorphism
with other diseases, such as schizophrenia [37],
neural tube defects [38], Alzheimer’s disease [39]
and coronary artery disease [40]. 
The  CBS  844ins68 polymorphism was first
reported in a homocystinuric patient by Sebastio et
al. [41]. It was initially thought to mandate the use
of an insertion-associated premature stop codon
in the CBS mRNA leading to the translation of
a truncated inactive enzyme. Subsequently Tsai et
al. [15] showed that the 68 bp insertion generates
an alternative splice site that permits the
elimination of the entire inserted region, thereby
allowing the formation of a normal mRNA transcript
and a fully functional CBS enzyme. In 1998, 
De Stefano et al. [42] reported that MTHFR 677TT
homozygous individuals carrying the CBS 844ins68
allele had lower homocysteine levels than 
non-carriers; however, folate levels were not
presented in this report. More recently, Dekou et al.
[43] also reported that the CBS 844ins68 allele
appears to have a homocysteine-lowering effect in
MTHFR 677TT homozygous individuals, but again
no data were reported regarding the effect on folate
levels. 
In our study, it was not possible to measure the
homocysteine and folate concentrations, but
studies have reported that individuals who have the
68 bp insertion had increased homocysteine and
folate levels compared with wild-type individuals
[44, 45].
For clinical histopathological parameters
analysed, our results suggest that the CBS  –
Insertion 68 bp allele was more frequent in patients
with the oral cavity as the primary site. The tumour
extent and lymph node involvement were not
associated with the presence of the polymorphism.
Kimura et al. [21] did not observe any association
between the polymorphism and clinical parameters
in prostate cancer.
The majority of HNSCC patients showed less
advanced stage classified as T1/T2 and N0 (54.3% and
96%, respectively) in our study. Different of the
literature data, which have shown a high frequency
of head and neck squamous cell carcinoma in
advanced stage (60% in stage III and IV) [46].
However, in gastric and cardiac cancer category
tumour size T1 and T2 was more prevalent, as in our
study in HNSCC [20].
No data were found in the literature assessing
survival according to the CBS 844ins68
polymorphism in patients with HNSCC. According
to Esher et al. [47], patients with HNSCC have a low
survival rate among some cancer types. In spite of
new surgical techniques, such as radiotherapy and
concomitant chemotherapy, there has not been
a significant increase in survival rate [48-50]. 
In conclusions, male gender and tobacco
consumption are associated with HNSCC risk and
there is no evidence of an association between CBS
polymorphism and head and neck carcinogenesis
risk. The polymorphism was associated with oral
cavity primary site and with less survival time.
Further studies in a larger population are required
to better understand this polymorphism. 
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